You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
SBC: ELDEC PHARMACEUTICALS INC. Topic: NIAIDHospital acquired pneumonia (HAP) is most common cause of mortality in intensive care units and the 2nd most common nosocomial infection in the US. P. aeruginosa, S. aureus (including MRSA) and other ESKAPE pathogens are common causes of HAP. The rise in antibiotic-resistant bacteria, including MRSA, further complicates the challenges of delivering effective treatments in this patient population. ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Eliminating the human factor from stereotaxic surgeries
SBC: POPNEURON LLC Topic: 104Project Summary: The main goal of this research project is to develop a new line of new stereotaxic devices for small animal research that outperforms existing devices in terms of accuracy, reproducibility, and ease of use. Advancing a tool such as an electrode, injection pipette or optical fiber through a small hole in the cranium, sometimes over long distances, and placing it precisely in a part ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Enabling comprehensive diagnosis of sub-acute infection in chronic respiratory disease via high sensitivity next generation sequencing
SBC: PEAK DIAGNOSTIC PARTNERS LLC Topic: NIAIDABSTRACT Sub-acute lung infections are increasingly recognized as drivers of poor symptom control among a subset of individuals with chronic lung disease (estimated more than 2 million for Asthma and COPD patients). When these sub-acute infections are diagnosed and treated appropriately, chronic lung disease patients can convert from moderate/severe to a milder disease phenotype, requiring lower m ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Engineering a unique antibody for patients with RA
SBC: ABWIZ BIO INC Topic: NIAIDRA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood.
SBC: Redbud Labs, Inc. Topic: 400ABSTRACT Microscale simulations have been applied to a number of complex microfluidic systems and biological applications, but existing methods are limited in the scale and scope of problems that are addressable. Thermodynamically constrained averaging theory (TCAT) is an established approach that can be used to formulate customized macroscale models that are consistent with microscale physics and ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Examination of a novel potential therapy for autonomic dysreflexia
SBC: Dignify Therapeutics LLC Topic: NINDSPROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
SBC: Planet Biotechnology Incorporated Topic: NIAIDLyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Treat Ulcerative Colitis
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: 300PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon m ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines
SBC: XDemics Corporation Topic: NCATSPROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health